LINCOLN

Lincoln Pharmaceuticals Share Price

₹771.70 -15 (-1.91%)

28 Dec, 2024 01:01

SIP TrendupStart SIP in LINCOLN

Start SIP

Performance

  • Low
  • ₹762
  • High
  • ₹794
  • 52 Week Low
  • ₹535
  • 52 Week High
  • ₹980
  • Open Price₹779
  • Previous Close₹787
  • Volume65,033

Investment Returns

  • Over 1 Month + 22.79%
  • Over 3 Month + 12.17%
  • Over 6 Month + 26.09%
  • Over 1 Year + 24.48%
SIP Lightning

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Invest Now

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 16
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 1,546
  • P/B Ratio
  • 2.6
  • Average True Range
  • 45.78
  • EPS
  • 48.25
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 42.02
  • RSI
  • 44.46
  • MFI
  • 41.44

Lincoln Pharmaceuticals Financials

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹771.70
-15 (-1.91%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹814.50
  • 50 Day
  • ₹763.46
  • 100 Day
  • ₹723.37
  • 200 Day
  • ₹677.54

Resistance and Support

776.03 Pivot Speed
  • R3 821.42
  • R2 807.73
  • R1 789.72
  • S1 758.02
  • S2 744.33
  • S3 726.32

What's your outlook on Lincoln Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals manufactures pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-malarial, and nutraceuticals. With state-of-the-art production facilities, it serves domestic and international markets, exporting products to over 60 countries globally.

Lincoln Pharmaceuticals has an operating revenue of Rs. 597.44 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 18% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at D- which indicates heavy supply, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-08 Quarterly Results
2024-05-16 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-02 Quarterly Results

Lincoln Pharmaceuticals F&O

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
0%
5.19%
36.14%
8.89%

About Lincoln Pharmaceuticals

  • NSE Symbol
  • LINCOLN
  • BSE Symbol
  • 531633
  • Managing Director
  • Mr. Mahendra G Patel
  • ISIN
  • INE405C01035

Similar Stocks to Lincoln Pharmaceuticals

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹771 As on 28 December, 2024 | 00:47

The Market Cap of Lincoln Pharmaceuticals is ₹1545.7 Cr As on 28 December, 2024 | 00:47

The P/E ratio of Lincoln Pharmaceuticals is 16 As on 28 December, 2024 | 00:47

The PB ratio of Lincoln Pharmaceuticals is 2.6 As on 28 December, 2024 | 00:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23